HNWAG
AUTL

High Net Worth Advisory Group’s Autolus Therapeutics AUTL Stock Holding History

High Net Worth Advisory Group’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,000
Closed -$8K – 672
2022
Q1 		$8K Buy
2,000
+1,000
+100% +$4.21K ﹤0.01% 549
2021
Q4 		$5K Buy
+1,000
New +$6K ﹤0.01% 596

Other funds holding AUTL

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

High Net Worth Advisory Group's AUTL Position: Q2 2022 in Review

High Net Worth Advisory Group sold out of Autolus Therapeutics (AUTL) in Q2 2022, closing a stake of 2,000 shares — an estimated $8K sold.

High Net Worth Advisory Group first reported a position in AUTL in Q4 2021 and held it in 2 quarters. The position peaked at $8K in Q1 2022. 67 funds tracked by Wall St. Rank hold AUTL as of Q2 2022.

  • High Net Worth Advisory Group reported no remaining Autolus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 2,000 Autolus Therapeutics shares in Q2 2022, an estimated $8K.
  • High Net Worth Advisory Group first reported a position in Autolus Therapeutics in Q4 2021 and held it in 2 quarters.
  • High Net Worth Advisory Group's Autolus Therapeutics position peaked at $8K in Q1 2022.
  • 67 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2022.

Based on High Net Worth Advisory Group's 13F filing for Q2 2022, filed 10 Aug 2022.